ACON ACLARION INC.

Aclarion to Present at the Planet MicroCap Showcase: VEGAS in Partnership with MicroCapClub

Aclarion to Present at the Planet MicroCap Showcase: VEGAS in Partnership with MicroCapClub

Wednesday, April 23, 2025 & 1x1 Meetings on Thursday, April 24, 2025

BROOMFIELD, Colo., April 09, 2025 (GLOBE NEWSWIRE) -- Aclarion, Inc., (“Aclarion” or the “Company”) (Nasdaq: ACON, ACONW), a healthcare technology company that is leveraging biomarkers and proprietary augmented intelligence (AI) algorithms to help physicians identify the location of chronic low back pain, today announced that it will be presenting at the Planet MicroCap Showcase: VEGAS 2025 in partnership with MicroCapClub on Wednesday, April 23, 2025 at 12:30 PM ET.

Brent Ness, CEO of Aclarion will be hosting the presentation and answering questions at the conclusion.

To access the live presentation, please use the following information:

Planet MicroCap Showcase: VEGAS 2025 in partnership with MicroCapClub

Date: Wednesday, April 23, 2025

Time: 12:30 PM ET

Webcast:

If you would like to schedule a 1x1 investor meeting and to attend the Planet MicroCap Showcase: VEGAS 2025 in partnership with MicroCapClub, please make sure you are registered here:

1x1 meetings will be scheduled and conducted in person at the conference venue: Paris Hotel & Casino in Las Vegas, NV. The Planet MicroCap Showcase: VEGAS 2025 in partnership with MicroCapClub website is available here:

If you can’t make the live presentation, all company presentations “webcasts” will be available directly on the conference event platform on this link under the tab “Agenda”:

About Aclarion, Inc.

Aclarion is a healthcare technology company that leverages Magnetic Resonance Spectroscopy (“MRS”), proprietary signal processing techniques, biomarkers, and augmented intelligence algorithms to optimize clinical treatments. The Company is first addressing the chronic low back pain market with Nociscan, the first, evidence-supported, SaaS platform to noninvasively help physicians distinguish between painful and nonpainful discs in the lumbar spine. Through a cloud connection, Nociscan receives magnetic resonance spectroscopy (MRS) data from an MRI machine for each lumbar disc being evaluated. In the cloud, proprietary signal processing techniques extract and quantify chemical biomarkers demonstrated to be associated with disc pain. Biomarker data is entered into proprietary algorithms to indicate if a disc may be a source of pain. When used with other diagnostic tools, Nociscan provides critical insights into the location of a patient’s low back pain, giving physicians clarity to optimize treatment strategies. For more information, please visit . 

Investor Contacts:

Kirin M. Smith

PCG Advisory, Inc.

Media Contact:

Jennie Kim

SPRIG Consulting



EN
09/04/2025

Underlying

ACONACLARION INC.

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on ACLARION INC.

 PRESS RELEASE
Free
ACON ACLARION INC.

Aclarion Publishes 2026 Shareholder Letter from the Chairman

Aclarion Publishes 2026 Shareholder Letter from the Chairman Company anticipates no capital raises prior to expected value enhancing catalysts Cash runway into 2028ATM terminated in early 2025 and ELOC expired December 31, 2025 BROOMFIELD, Colo., Feb. 05, 2026 (GLOBE NEWSWIRE) -- Aclarion, Inc., (“Aclarion” or the “Company”) (Nasdaq: ACON, ACONW), a commercial-stage healthcare technology company that is leveraging biomarkers and proprietary augmented intelligence (AI) algorithms to help physicians identify the location of chronic low back pain, today announced the release of its 2026 Sha...

February 5, 2026 1 EN
 PRESS RELEASE
Free
ACON ACLARION INC.

Aclarion Adds High-Volume Practice, Source Healthcare, to Support Noci...

Aclarion Adds High-Volume Practice, Source Healthcare, to Support Nociscan Growth and Real-World Evidence Generation Expands availability of Nociscan in the greater Los Angeles areaReinforces Nociscan’s non-invasive advantage with real-world clinical validation compared to anesthetic discography, a spinal injection procedureSupports scalable growth strategy while building data assets critical to payer and provider adoption BROOMFIELD, Colo., Feb. 03, 2026 (GLOBE NEWSWIRE) -- ., (“Aclarion” or the “Company”) (Nasdaq: ACON, ACONW), a commercial-stage healthcare technology company that is l...

February 3, 2026 1 EN
 PRESS RELEASE
Free
ACON ACLARION INC.

Aclarion Strengthens Balance Sheet and Extends Cash Runway Into 2028

Aclarion Strengthens Balance Sheet and Extends Cash Runway Into 2028 Debt-Free Balance Sheet With $21.6 Million in Cash BROOMFIELD, Colo., Jan. 13, 2026 (GLOBE NEWSWIRE) -- ., (“Aclarion” or the “Company”) (Nasdaq: ACON, ACONW), a commercial-stage healthcare technology company that is leveraging biomarkers and proprietary augmented intelligence (AI) algorithms to help physicians identify the location of chronic low back pain, today announced the closing of a $10.4 million common-stock-only financing at $5.18 per share in a clean capital raise structure. The transaction materially stren...

January 13, 2026 1 EN
 PRESS RELEASE
Free
ACON ACLARION INC.

Aclarion Provides 2025 Update and 2026 Corporate Outlook

Aclarion Provides 2025 Update and 2026 Corporate Outlook Quarterly Nociscan scan volumes increased 114% year-over-year in Q4 2025Annual Nociscan scan volumes increased 69% year-over-year in 2025Debt-free balance sheet with $12.0 million in cash as of December 31, 2025, extending cash runway into 2027 and providing strategic flexibility for continued commercial growthCompany aims to enroll approximately 25% of patients in CLARITY trial by the end of Q2 2026, with the first internal readout on interim data anticipated in Q3 2026 BROOMFIELD, Colo., Jan. 08, 2026 (GLOBE NEWSWIRE) -- ., (“Acl...

January 8, 2026 1 EN
 PRESS RELEASE
Free
ACON ACLARION INC.

Aclarion Announces First Patient Enrollments at Two Additional CLARITY...

Aclarion Announces First Patient Enrollments at Two Additional CLARITY Trial Sites and Provides Guidance on Expected Availability of Initial Data Northwestern and Scripps Health join two previously announced sites in achieving this critical patient enrollment milestone Seven leading U.S. spine centers have now completed the regulatory and operational requirements to screen and enroll patients in CLARITY First readout on interim data expected after initial cohort of patients achieves 3-month follow up visit in 3Q 2026 BROOMFIELD, Colo., Jan. 06, 2026 (GLOBE NEWSWIRE) -- ., (“Aclarion” or...

January 6, 2026 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch